Annie Talbot
Academic Appointments
- Clinical Assistant Professor, Medicine - Infectious Diseases
Key Documents
Contact Information
-
Clinical Offices
Positive Care Clinic 3351 El Camino Real Suite 225 Atherton, CA 94027 Tel Work (650) 723-9001 Fax (650) 568-1708
- Academic Offices
Personal Information Email Tel (650) 723-9001Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Family Medicine
Professional Education
| Board Certification: | Family Medicine, American Board of Family Medicine (2009) |
| Residency: | University of Sherbrooke, Canada (1999) |
| Medical Education: | University of Montreal, Canada (1997) |
Graduate & Fellowship Program Affiliations
Community and International Work
- Mental health care and HIV prevention, International
Scientific Focus
Current Research Interests
A pilot study integrating HIV prevention and care with treatment of psychological trauma in vulnerable Rwandan youth: A community-based pilot intervention. Collaboration between Stanford University and Rwanda NGO, Uyisenga NManzi.
Clinical Trials
- Recruiting Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
- Not Recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
- Not Recruiting HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth
- Not Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
- Not Recruiting Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Publications
- Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS. 2011; (2): 211-20
- Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010; (6): 2473-9
- Switch from Enfuvirtide to Raltegravir in patients with indetectable viral load: Efficacy and safety at 24 weeks in a Montreal Cohort JAIDS. 2009; (3): 361-364
- Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol. 2009; (4): 305-8
- Acute renal failure in 4 HIV-Infected patients: potential association with Tenofovir and ARVs Canadian Journal of Infectious Disease and Medical Microbiology. 2008; (1): 75-76
- La prise en charge et le traitement des personnes co-infectées par le virus de limmunodéficience humaine (VIH) et de lhépatite B (VHB) Guide pour les professionnels de la santé du Québec. 2008; (1)
Help